Literature DB >> 36005812

Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide.

Michael W Lutz1, Ara S Khachaturian2, Henrik Zetterberg3,4,5,6,7, Kaj Blennow8, Auriel A Willette9,10, Michelle M Mielke11, Kathleen M Hayden12, Hiroko H Dodge13, Yi Tang14, Barry D Greenberg15,16, Walter A Kukull17, Zaven S Khachaturian2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36005812      PMCID： PMC9514317          DOI： 10.1002/alz.12772

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   16.655


× No keyword cloud information.
  14 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease.

Authors:  Zaven S Khachaturian
Journal:  Neurobiol Aging       Date:  2002 Jul-Aug       Impact factor: 4.673

3.  New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia.

Authors:  Ara S Khachaturian; Kathleen M Hayden; Michelle M Mielke; Yi Tang; Michael W Lutz; Michael Gold; Walter A Kukull; Richard Mohs; Serge Gauthier; José Luis Molinuevo; Henrik Zetterberg; Zaven S Khachaturian
Journal:  Alzheimers Dement       Date:  2018-05-26       Impact factor: 21.566

4.  Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

Authors:  Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel
Journal:  Alzheimers Dement       Date:  2016-11-18       Impact factor: 21.566

5.  Alzheimer's Disease Interventions: Implications of therapeutic promises amidst questions and doubts about clinically meaningful outcomes.

Authors: 
Journal:  Alzheimers Dement       Date:  2021-10       Impact factor: 21.566

6.  "Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?

Authors:  John C S Breitner; Hiroko H Dodge; Zaven S Khachaturian; Ara S Khachaturian
Journal:  Alzheimers Dement       Date:  2022-03-04       Impact factor: 16.655

Review 7.  Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics.

Authors:  Henrik Zetterberg; Kaj Blennow
Journal:  Mol Neurodegener       Date:  2021-02-19       Impact factor: 14.195

Review 8.  Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020.

Authors:  Elisabeth Bakker; Natalie M Hendrikse; Falk Ehmann; Daniëlla S van der Meer; Jordi Llinares Garcia; Thorsten Vetter; Viktoriia Starokozhko; Peter G M Mol
Journal:  Clin Pharmacol Ther       Date:  2022-03-05       Impact factor: 6.903

9.  Adding Rigor to Biomarker Evaluations-EDRN Experience.

Authors:  Ziding Feng; Margaret S Pepe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-11-10       Impact factor: 4.254

10.  Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.

Authors:  Margaret S Pepe; Ziding Feng; Holly Janes; Patrick M Bossuyt; John D Potter
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.